Antiretroviral therapy and HIV‐associated cardiovascular disease: a prospective cardiac biomarker and CMR tissue characterization study

Abstract

AbstractAimsBiochemical markers are fundamental in cardiac evaluation, and various novel assays have recently been discovered. We prospectively evaluated the hearts of newly diagnosed people living with human immunodeficiency virus (PLWH) using cardiac biomarkers, compared them with human immunodeficiency virus (HIV)‐uninfected controls, and correlated our prospective findings with cardiovascular magnetic resonance imaging (CMR).Methods and resultsNewly diagnosed, antiretroviral therapy (ART)‐naïve PLWH were recruited along with HIV‐uninfected, age‐matched, and sex‐matched controls. All participants underwent measurement of high‐sensitivity cardiac troponin T (hs‐cTnT), N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), soluble ST2 (sST2), and galectin‐3, as well as a CMR study with multiparametric mapping. The HIV group started ART and was re‐evaluated 9 months later. The cardiac biomarkers and their correlation with CMR parameters were evaluated in and between groups. Compared with controls (n = 22), hs‐cTnT (4.0 vs. 5.1 ng/L; P = 0.004), NT‐proBNP (23.2 vs. 40.8 ng/L; P = 0.02), and galectin‐3 (6.8 vs. 9.0 ng/mL; P = 0.002) were all significantly higher in the ART‐naïve group (n = 73). After 9 months of ART, hs‐cTnT (5.1 vs. 4.3 ng/L; P = 0.02) and NT‐proBNP (40.8 vs. 28.5 ng/L; P = 0.03) both decreased significantly and a trend of decrease was seen in sST2 (16.5 vs. 14.8 ng/L; P = 0.08). Galectin‐3 did not demonstrate decrease over time (9.0 vs. 8.8 ng/mL; P = 0.6). The cardiac biomarkers that showed the best correlation with CMR measurements native T1, T2, and extracellular volume were NT‐proBNP (rs ≥ 0.4, P < 0.001) and galectin‐3 (rs ≥ 0.3, P < 0.01).ConclusionsOur cardiac biomarker data support the presence of subclinical myocardial injury, remodelling, and fibrosis at HIV diagnosis, and ART had a positive influence on these blood markers. It remains unclear if the underlying pathological processes were fully addressed by ART. The ability of cardiac biomarkers to detect and track tissue abnormalities diagnosed with CMR showed promise. With additional research, this could lead to improvements in screening and monitoring myocardial abnormalities, even in CMR‐limited settings.